SG Americas Securities LLC Sells 8,414 Shares of Fulgent Genetics, Inc. (NASDAQ:FLGT)

SG Americas Securities LLC lowered its holdings in shares of Fulgent Genetics, Inc. (NASDAQ:FLGTGet Rating) by 40.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 12,392 shares of the company’s stock after selling 8,414 shares during the quarter. SG Americas Securities LLC’s holdings in Fulgent Genetics were worth $773,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently bought and sold shares of the company. Geode Capital Management LLC raised its holdings in Fulgent Genetics by 4.0% in the 4th quarter. Geode Capital Management LLC now owns 374,211 shares of the company’s stock worth $37,641,000 after acquiring an additional 14,369 shares during the period. Pacer Advisors Inc. raised its holdings in Fulgent Genetics by 105.4% in the 1st quarter. Pacer Advisors Inc. now owns 301,149 shares of the company’s stock worth $18,795,000 after acquiring an additional 154,566 shares during the period. Skandinaviska Enskilda Banken AB publ raised its holdings in Fulgent Genetics by 1,282.3% in the 4th quarter. Skandinaviska Enskilda Banken AB publ now owns 278,875 shares of the company’s stock worth $28,331,000 after acquiring an additional 258,700 shares during the period. Northern Trust Corp raised its holdings in Fulgent Genetics by 0.4% in the 4th quarter. Northern Trust Corp now owns 260,588 shares of the company’s stock worth $26,213,000 after acquiring an additional 1,134 shares during the period. Finally, Nepsis Inc. raised its holdings in Fulgent Genetics by 19.6% in the 1st quarter. Nepsis Inc. now owns 112,306 shares of the company’s stock worth $7,009,000 after acquiring an additional 18,430 shares during the period. Institutional investors own 37.61% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Piper Sandler dropped their price objective on shares of Fulgent Genetics from $85.00 to $70.00 in a report on Sunday, May 15th. TheStreet downgraded shares of Fulgent Genetics from a “b-” rating to a “c+” rating in a report on Thursday, July 28th.

Insider Activity

In other news, COO Jian Xie sold 1,269 shares of Fulgent Genetics stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $53.38, for a total transaction of $67,739.22. Following the sale, the chief operating officer now directly owns 329,701 shares in the company, valued at approximately $17,599,439.38. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Fulgent Genetics news, COO Jian Xie sold 1,269 shares of the business’s stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $53.38, for a total value of $67,739.22. Following the transaction, the chief operating officer now directly owns 329,701 shares in the company, valued at $17,599,439.38. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Paul Kim sold 1,191 shares of the business’s stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $53.38, for a total transaction of $63,575.58. Following the completion of the transaction, the chief financial officer now owns 153,577 shares in the company, valued at $8,197,940.26. The disclosure for this sale can be found here. In the last three months, insiders have sold 3,200 shares of company stock worth $171,530. Corporate insiders own 29.50% of the company’s stock.

Fulgent Genetics Stock Performance

Shares of Fulgent Genetics stock opened at $59.54 on Tuesday. The firm’s 50-day simple moving average is $55.24 and its 200-day simple moving average is $58.50. Fulgent Genetics, Inc. has a twelve month low of $47.34 and a twelve month high of $112.00. The firm has a market cap of $1.81 billion, a P/E ratio of 4.03 and a beta of 1.47.

Fulgent Genetics (NASDAQ:FLGTGet Rating) last issued its earnings results on Tuesday, May 3rd. The company reported $4.93 earnings per share for the quarter, beating the consensus estimate of $4.32 by $0.61. Fulgent Genetics had a net margin of 48.32% and a return on equity of 41.13%. The business had revenue of $320.30 million for the quarter, compared to analyst estimates of $300.50 million. During the same period in the previous year, the business earned $6.51 EPS. The firm’s revenue was down 10.9% on a year-over-year basis. On average, equities analysts forecast that Fulgent Genetics, Inc. will post 5.71 earnings per share for the current fiscal year.

Fulgent Genetics Profile

(Get Rating)

Fulgent Genetics, Inc, together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests.

Recommended Stories

Institutional Ownership by Quarter for Fulgent Genetics (NASDAQ:FLGT)

Want More Great Investing Ideas?

Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter.